| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This market insight report presents an in depth analysis of hERG Screening
market. The study emphasizes on both the technology and product segments of
hERG Screening in biotechnology and pharmaceutical application areas. The
report provides essential information including market data, segmentation,
market size, key trends, M&A, product developments, industry forecasts,
corporate intelligence, and other relevant information. The report lists 128
companies that are engaged in hERG Screening services and/or production of
hERG Screening tools/instruments. Projections and estimates are graphically
represented by region. A global perspective is presented along with regional
analysis covering the regions of North America, Europe, Asia-Pacific and Rest
of World. The market is analyzed in US Dollars and includes 32 exclusive
exhibits.
TABLE OF CONTENTS
I. SCOPE AND METHODOLOGY
II. REPORT SYNOPSIS
- 1. Introduction
- hERG Screening
- Normal Functioning of Heart
- About the Heart
- Electrocardiogram (EKG or ECG)
- 2.Global Market Analysis
- Exhibit 1: hERG Screening (2005-2012) - Global Market Analysis (Current
& Future) in US$ Million (Graphical Representation Included)
- Exhibit 2: List of Major Global Companies
- 3. Regional Market Analysis
- North America
- Exhibit 3: hERG Screening (2005-2012) - North American Market Analysis
(Current & Future) in US$ Million(Graphical Representation Included)
- Major Companies in North America
- ABR-Affinity BioReagents, Inc. (USA)
- Aurora Biomed, Inc. (Canada)
- AutoMate Scientific, Inc. (USA)
- AVIVA Biosciences Corporation (USA)
- Caliper Life Sciences, Inc.(USA)
- Cellular Dynamics International (USA)
- ChanTest Corporation (USA)
- Charles River Laboratories, Inc. (USA)
- CorDynamics (USA)
- Covance, Inc. (USA)
- Invitrogen, Inc. (USA)
- Lifespan Biosciences, Inc. (USA)
- MDS, Inc (Canada)
- Millipore Corporation (USA)
- Molecular Devices Corporation (USA)
- Neurion Pharmaceuticals, Inc. (USA)
- Novascreen Biosciences Corporation (USA)
- Novus Biologicals, Inc. (USA)
- Santa Cruz Biotechnology, Inc. (USA)
- Schrodinger, LLC (USA)
- Sigma-Aldrich Corporation (USA)
- Tocris Bioscience (USA)
- Wisconsin Alumni Research Foundation (WARF) (USA)
- Europe
- Exhibit 4: hERG Screening (2005-2012) - European Analysis (Current &
Future) in US$ Million (Graphical Representation Included)
- Major Companies in Europe
- Abcam PLC (UK)
- Astrazeneca PLC (UK)
- Aureus Pharma (France)
- bSys GmbH (Switzerland)
- Cambridge BioScience Ltd (UK)
- Cerep SA (France)
- ChemAxon Kft. (Hungary)
- CreaCell (France)
- Cyprotex plc (UK)
- Cytocentrics AG (Germany)
- Flyion GmbH (Germany)
- Nanion Technologies GmbH (Germany)
- Neurosolutions Ltd. (UK)
- RCC Ltd. (Switzerland)
- Sophion Bioscience A/S (Denmark)
- Asia-Pacific
- Exhibit 5: hERG Screening (2005-2012) -Asia-Pacific Market Analysis
(Current & Future) in US$ Million(Graphical Representation Included)
- Major Companies in Asia-Pacific
- Abnova Corp. (Taiwan)
- RDDT (Australia)
- Strand Life Sciences (India)
- Synergia Life sciences (India)
- Tetra Q (Australia)
- WuXi PharmaTech Co.Ltd (China)
- Rest of World
- Exhibit 6: hERG Screening (2005-2012) - Rest of World* Market Analysis
(Current & Future) in US$ Million(Graphical Representation Included)
- More About the Patch Clamp Technique
- Short QT Syndome
- Long QT syndrome
- Signs and symptoms
- Causes
- QT interval
- Types of LQTS
- Genetical LQTS
- Acquired LQTS
- The Long QT syndrome and Torsade de pointes
- Recording the Electrical Activity of Heart Beat
- Diagnosis of LQTS
- Treatment
- Cell Lines
- Qualified Cell Lines for Cell-Based ADME and Toxicity Evaluation
III. PRODUCT/TECHNOLOGY RESEARCH
- 1. Introduction
- hERG Screening Growth Trends - Global Markets
- Exhibit 7: Global* Market for hERG Screening: Geographic Regions
(Asia-Pacific, Europe, Canada, Japan and United States) Ranked by
Projected CAGR for 2005 through 2012 (Graphical Representaton Included)
- Ion Channels
- History
- Basic Features of Ion Channel
- Biological Role
- The Patch Clamp Technique
- Methodology
- Technique Configurations
- The On-cell
- The Inside out
- The Whole-cell
- The Outside out
- The Perforated whole-cell
- The Patch Clamp Technique Application
- QPatch 16
- QPatch HT
- Exhibit 8: List of Companies Developing Patch clamp
- Q Patch Applications
- QPATCH HT: Effective Application in Ion Channel Drug Discovery
- Screening Station
- Plates
- Cell Preparation Unit
- Liquid Handling System
- Touch Screen
- About Q Plate
- The Q Plate Technique
- Q Plate Prospects
- Data Acquisition
- Q Patch software
- Exhibit 9: Companies Developing hERG Soft Ware
- Types of Ion Channels
- Voltage-gated Ion Channel
- Ligand-gated Ion Channel
- Introduction
- Regulation
- Clinical Relevance
- Diversity of Ion Channels
- Potassium Channels
- Voltage-gated Potassium Channels
- Diseases Related to Ion Channels
- Exhibit 10: Diseases Related to Ion Channel Function
- Ion Channel Genes of the Human Genome
- Ion Channels as Drug Targets
- Technologies for Ion Channel Characterization
- Cell Lines
- Exhibit 11: Companies Developing Cell lines for hERG Screening
- Application of HEK 293 Cells
- CHO or Chinese Hamster Ovary Cells
- Transfection
- Calcium Phosphate Transfection
- Normal Cardiac Cycle
- Definition
- Role of Potassium, Magnesium and Calcium in Normal Functioning of Heart
- Magnesium
- Calcium
- Potassium
- Membrane Potential
- Improper Membrane Potential
- Description
- Task in Human Well being
- Common Abnormalities and Ailments
- Atrial Arrhythmias
- Ventricular Arrhythmias
- Cardiac Phase
- Blood Pressure
- Electrocardiogram (EKG or ECG):
- History
- QRS Complex:
- T wave
- Abnormality in Potassium Ion Channel:
- Short QT Syndrome
- Arrhythmia:
- Torsades de Pointes : a cardiac arrhythmia
- Characteristics of TdP
- Causes of TdP
- Risk factors for TdP
- Treatment
- QT Interval
- Long QT Syndrome
- LQTS - The Causes
- LQTS - Risks
- LQTS - Signs and Symptoms
- Screening and Diagnostic Procedures
- Complications
- LQTS - Treatment
- Medical Devices and Surgical Procedures
- Clinical Trials
- LQTS - The Types
- Inherited Long QT syndrome
- Exhibit 12: Drugs to be Avoided by Congenital QT Patients
- Exhibit 13: Drugs (Withdrawn From Market) Avoided by Congenital QT
Patients
- Genetic Basis and Treatment
- Genetic Basis of LQTS
- LQTS Associated Syndromes
- Exhibit 14: Drugs Which Block the hERG Channel.
- Cofactors of Drug Induced LQTS:
- Symptoms for Identification of Drug Induced LQTS
- High probability of Drug Induced LQTS
- Suspected Cases of Drug Induced LQTS
- Unlikely Case of Drug Induced LQTS
- Functioning of Heart
- Drug Discovery Concerns
- Action from Drug Approving Authorities
- Exhibit 15: Drugs (Discontinued in the Market) which Block the hERG
Channel.
- Role of hERG Blockers in Cardiac Disorders
- The characteristics and Clinical Applications of Cardiac hERG/I (Kr)
Potassium Channel
- Cibenzoline an effective Na+-channel blocker
- Biophysical Properties and Molecular Determinants of ziprasidone and
its Role in Block Opening hERG
- In silico Modeling in hERG Channel Blockers
- hERG Channel Archetypes and Pharmacophores
- In silico Model Improvement and Assessment of HERG Binding
- Testing In Silico for hERG K+ Channel Blockers
- In Silico Categorization of hERG Channel Blockers: a Skill-Based Strategy
- hERG Screening - Drugs Banned
- Exhibit 16: List of Banned Drugs for Inducing LQTS
- 2. Product Trends
- The GLP hERG Channel Assay
- Benefits Attributed to the Use of CDI Services
- ICR 8000 - The latest Entrant in the Ion Channel Technology
- Applications of ICR 800
- Features and Parameters of ICR 800
- Features and Parameters of ICR 12000
- Exhibit 17: Companies Offering hERG Screening Services
- Rubidium Flux Assay
- IonWorks® HT in hERG Channel Screening
- Measurement of hERG Channel Currents Using IonWorks HT System
- Sophion's Q Patch
- QPatch 16
- QPatch HT
- Cell Lines in hERG Screening:
IV. MARKET DYNAMICS
- 1. Market Overview
- Global Market Analysis
- Exhibit 18: hERG Screening (2005-2012) - Global Market Analysis
(Current & Future) by Geographic Region for North America, Europe,
Asia-Pacific and Rest of World in US$ Million (Graphical Representation
Included)
- Exhibit 19: hERG Screening (2006, 2009, 2012) Percentage Breakdown of
Global Market value by Geographic Region for North America, Europe,
Asia-Pacific and Rest of World (Graphical Representation Included)
- 2. Major Companies in hERG Screening Industry
- Abcam PLC (UK)
- Abnova Corp. (Taiwan)
- ABR-Affinity BioReagents, Inc. (USA)
- Astrazeneca PLC (UK)
- Aureus Pharma (France)
- Aurora Biomed, Inc. (Canada)
- AutoMate Scientific, Inc. (USA)
- AVIVA Biosciences Corporation (USA)
- bSys GmbH (Switzerland)
- Caliper Life Sciences, Inc. (USA)
- Cambridge BioScience Ltd (UK)
- Cellular Dynamics International (USA)
- Cerep SA (France)
- ChanTest Corporation (USA)
- Charles River Laboratories, Inc. (USA)
- ChemAxon Kft. (Hungary)
- CorDynamics (USA)
- Covance, Inc. (USA)
- CreaCell (France)
- Cyprotex plc (UK)
- Cytocentrics AG (Germany)
- Flyion GmbH (Germany)
- Invitrogen, Inc. (USA)
- Lifespan Biosciences, Inc. (USA)
- MDS, Inc (Canada)
- Millipore Corporation (USA)
- Molecular Devices Corporation (USA)
- Nanion Technologies GmbH (Germany)
- Neurion Pharmaceuticals, Inc. (USA)
- Neurosolutions Ltd. (UK)
- Novascreen Biosciences Corporation (USA)
- Novus Biologicals, Inc. (USA)
- RCC Ltd. (Switzerland)
- RDDT (Australia)
- Santa Cruz Biotechnology, Inc. (USA)
- Schrodinger, LLC (USA)
- Sigma-Aldrich Corporation (USA)
- Sophion Bioscience A/S (Denmark)
- Strand Life Sciences (India)
- Synergia Life sciences (India)
- Tetra Q (Australia)
- Tocris Bioscience (USA)
- Wisconsin Alumni Research Foundation (WARF) (USA)
- WuXi PharmaTech Co.Ltd (China)
- 3. Major Activities in hERG Screening Industry
- Novel Cardiac Model Developed by PhysioStim to Investigate Compound
Assays
- Neuromed Licenses AurSCOPE Ion Channel Database from Aureus Pharma
- PhysioStim Deploys the Innovative Cardiac Pharmacological System
- TetraQ to Market NeuroSolutions' Products in Australasia
- Charles River Laboratories to Start a New Pre-Clinical Services Facility
in Quebec
- Charles River Laboratories Completes Joint Venture with Shanghai
BioExplorer
- Aureus Pharma Forms Alliance with MDL® Isentris®
- Millipore Provides First L-type Calcium Channel for Drug Testing
- Aureus Pharma Grants License to Bayer CropScience for its AurSCOPE
Knowledge Databases Cerep Extends Pharmaco-Informatics Alliance with Pfizer
- Cerep Renews Agreement for 2007 with Eli Lilly
- Covance Acquires Orbitrap™ to Become the First CRO with Latest
Mass Spectrometer Technology
- AVIVA Biosciences Signs Distribution Agreement with Cosmo Bio Making
Available its Electrophysiology Service in Japan
- Covance Granted License for B-CLEAR® to Predict In-vivo Liver
Disposition from In-vitro Assessments
- Joint Venture Between Strand and BioIT Alliance
- Sophion Bioscience Introduces New Revolutionary QPatch HT
- Origenis Becomes First Customer to Aureus Pharma's AurWEB
- Aureus Pharma Signs License Agreement with Xention for AurSCOPE Ion
Channel Knowledge Database
- Aureus Pharma Licenses Three Knowledge Databases to Siena Biotech S.p.A.
- Joint Venture between TetraQ and VivoPharma for New Pre-Clinical Drug
Development Services
- Serologicals Corporation Acquires Cytomyx
- Aureus Pharma Launches AurWEB™ - The New Web Portal Solution for
Knowledge Driven Drug Discovery
- Strand and Pharmidex to Jointly Develop New Silico Technology for CNS
Drug Discovery
- GlaxoSmithKline Granted License to Use Aureus Pharma's Knowledge
Databases
- Strand Signs Agreement with ChemAxon to Develop New Software
- Sophion Bioscience Initiates Joint Venture with Merck on QPatch HT
- Sophion Enters Japanese Market
- Bio-Rad Forms a Joint Venture with Aureus Pharma and Equbits LLC for In
Silico Prediction of Biological Properties in Preclinical Drug Research
- Aureus Pharma Extends Alliance with Sanofi-Aventis
- Cyprotex Introduces New Innovative Screening Service
- Sophion and Hydra Form One-of-a-Kind Reference Site for QPatch Automated
Patch Clamp System
- Aureus Pharma Launches AurSCOPE® hERG Channel - The New Cardio
- toxicity Related Database
- Molecular Devices Launches New IonWorks® Quattro™ System for
Accelerated Ion Channel Screening
- 4. Regional Market Analysis
- A. North America
- Market Analysis
- Exhibit 20: hERG Screening(2005-2012) - North American Market
Analysis (Current & Future) in US$ Million (Graphical Representation
Included)
- Exhibit 21: List of Major Companies in North America
- Analysis by Geographic Region
- Exhibit 22: hERG Screening (2005-2012) - North American Market
Analysis (Current & Future) by Geographic Region for United States and
Canada in US$ Million (Graphical Representation Included)
- Exhibit 23: hERG Screening (2006, 2009, 2012) Percentage Breakdown
of North American Market Value by Geographic Regions for United States
and Canada (Graphical Representation Included)
- B. Europe
- Market Analysis
- Exhibit 24: hERG Screening (2005-2012) - European Market Analysis
(Current & Future) in US$ Million (Graphical Representation Included)
- Exhibit 25: List of Major Companies in Europe
- Analysis by Geographic Region
- Exhibit 26: hERG Screening (2005-2012) - European Market Analysis
(Current & Future) by Geographic Region for United Kingdom, Germany,
France, Switzerland, and Rest of Europe in US$ Million (Graphical
Representation Included)
- Exhibit 27: hERG Screening (2006, 2009, 2012) Percentage Breakdown
of Europe Market Value by Geographic Regions for United Kingdom Germany,
France, Switzerland and Rest of Europe(Graphical Representation Included)
- C. Asia-Pacific
- Market Analysis
- Exhibit 28: hERG Screening (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) in US$ Million (Graphical Representation
Included)
- Exhibit 29: List of Major Companies in Asia-Pacific
- Analysis by Geographic Region
- Exhibit 30: hERG Screening (2005-2012) - Asia-Pacific Market
Analysis (Current & Future) by Geographic Region for Australia, China,
India, and Rest of Asia-Pacific in US$ Million (Graphical Representation
Included)
- Exhibit 31: hERG Screening (2006, 2009, 2012) Percentage Breakdown
of Asia-Pacific Market Value by Geographic Regions for Australia, China,
India and Rest of Asia-pacific (Graphical Representation Included)
- D. Rest of World
- Market Analysis
- Exhibit 32: hERG Screening (2005-2012) - Rest of World Market
Analysis (Current & Future) in US$ Million (Graphical Representation
Included)
- 5. hERG Screening -The Industry Out Look
V. CORPORATE DIRECTORY
|
